Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery.
Antipsychotic activity
Aripiprazole
Box-Behnken statistical design
Brain pharmacokinetics
Intranasal delivery
Mucoadhesive nanoemulsion
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
18
12
2020
revised:
12
01
2021
accepted:
19
01
2021
pubmed:
31
1
2021
medline:
22
6
2021
entrez:
30
1
2021
Statut:
ppublish
Résumé
Delivering therapeutics to the brain using conventional dosage forms is always a challenge, thus the present study was aimed to formulate mucoadhesive nanoemulsion (MNE) of aripiprazole (ARP) for intranasal delivery to transport the drug directly to the brain. Therefore, a TPGS based ARP-MNE was formulated and optimized using the Box-Behnken statistical design. The improved in vitro release profile of the formulation was in agreement to enhanced ex vivo permeation through sheep mucous membranes with a maximum rate of permeation co-efficient (62.87 cm h
Identifiants
pubmed: 33515583
pii: S0022-3549(21)00036-8
doi: 10.1016/j.xphs.2021.01.021
pii:
doi:
Substances chimiques
Antipsychotic Agents
0
Emulsions
0
Vitamin E
1406-18-4
Aripiprazole
82VFR53I78
tocophersolan
O03S90U1F2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1761-1778Informations de copyright
Copyright © 2021 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.